Latest news

Thumbnail image for Vertex, NHS England no closer to Orkambi settlement

Vertex, NHS England no closer to Orkambi settlement

Vertex and NHS England remain locked in a battle over the provision of cystic fibrosis drug Orkambi, seemingly no closer to a settlement that would allow patients access to the drug on the NHS.

9th July 2018

Thumbnail image for If you love a challenge, ENTER NOW

If you love a challenge, ENTER NOW

The PharmaTimes Marketer of the Year competition is celebrating it's 25th anniversary and with a number companies including Sanofi, PharmaLex, Thornton & Ross, Roche, Bayer, Consilient Health, Cycle Pharmaceuticals and others already entered, it could just be the most exciting one to date.

6th July 2018

Thumbnail image for Chinese firms eyeing up Sinclair Pharma

Chinese firms eyeing up Sinclair Pharma

Shares in UK group Sinclair Pharma shot up nearly 40 percent after it confirmed interest from Chinese firms with regard to a possible take-over.

6th July 2018

Thumbnail image for Pfizer UK MD takes the helm at the ABPI

Pfizer UK MD takes the helm at the ABPI

Erik Nordkamp, managing director of Pfizer UK, has been named as the new president of the Association of the British Pharmaceutical Industry (ABPI).

6th July 2018

Thumbnail image for Survey shows public support for NHS tax rise

Survey shows public support for NHS tax rise

The vast majority of the public would be willing to accept tax increases to secure significant improvements in the NHS, finds a new poll by Ipos Mori commissioned by the NHS Confederation.

5th July 2018

Thumbnail image for Final NICE no for BMS’ Opdivo in urothelial carcinoma

Final NICE no for BMS’ Opdivo in urothelial carcinoma

The National Institute for Health and Care Excellence has now issued final guidance rejecting NHS funding for use of Bristol-Myers Squibb’s Opdivo as a treatment for locally advanced unresectable or metastatic urothelial carcinoma (mUC).

4th July 2018

Thumbnail image for MSD’s antiviral Prevymis fails to win NICE backing

MSD’s antiviral Prevymis fails to win NICE backing

MSD’s Prevymis has not won the support of NHS cost regulators for preventing cytomegalovirus (CMV) reactivation and disease in prone adults who have received an allogeneic haematopoietic stem cell transplant (HSCT).

4th July 2018

Previous  --   5 6 7 8 9 10 11 12 13 14   --  Next

Latest jobs

View all

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download